Australia Inks Next-Gen mRNA Technology Deal With US

Commonwealth Serum Laboratories (CSL), an Australian biotechnology company and the world’s second-biggest flu vaccine manufacturer, has agreed to pay $312 million ($US200 million) to use groundbreaking mRNA vaccine technology from a U.S. company.

The vaccine manufacturer announced on Nov. 2 that it had licenced the new technology with Arcturus Therapeutics, an American mRNA medicines biotechnology company.

“This collaboration is an exciting opportunity to complement CSL’s own next-generation mRNA program with a partner who developed a platform to deliver late-stage clinical supplies at scale,” CSL Chief Operating Officer Paul McKenzie said in a statement.

“These combined capabilities will accelerate our journey in mRNA.”

Arcturus’s mRNA vaccines use “self-amplifying” technology which studies have shown creates copies of themselves within the body so that they would require much smaller doses than the multiple doses required with current mRNA vaccines.

It is now working on its own mRNA-based vaccine for COVID-19, influenza, and other respiratory diseases.

CSL’s chief medical officer Dr Bill Mezzanotte said that this collaboration on next-generation mRNA is another example of the company’s “relentless pursuit of disruptive innovation.”

“We look forward to working closely with Arcturus to shape the future therapeutic landscape of influenza vaccines and also using this exciting scientific and strategic platform to develop and commercialise vaccines for other seasonal and pandemic respiratory viruses with high unmet need,” Mezzanotte, who has also spent 16 years with AstraZeneca, said.

CSL was established in Australia in 1916 to service the health needs of a nation in the middle of World War I. After a century, it has become a global leader in vaccines for rare and serious diseases, including influenza, polio, and other infectious diseases.

Surgeon Warns mRNA Vaccines Are Killing Men

Florida’s Surgeon-General Joseph A. Ladapo recently warned that the COVID-19 mRNA vaccines significantly increase the risk of death from heart problems, especially in men.

“This analysis found that there is an 84 percent increase in the relative incidence of cardiac-related death among males 18–39 years old within 28 days following mRNA vaccination,” he said.

“This is not the first study to find an increased risk of cardiovascular adverse outcomes with specifically the mRNA COVID-19 vaccines.”

However, in the act of information suppression, Twitter deleted some of the information from the surgeon.

Meanwhile, more data has been coming out that different journals have falsified information.

For instance, a leading medical journal was recently found to have skewed data in a peer-reviewed study on vaccinations by grouping people who had natural immunity from COVID-19 with data on people who received the vaccines.

Jessie Zhang


Jessie Zhang is a reporter based in Sydney covering Australian news, focusing on health and environment. Contact her at

Source link